Dokumentumok
KPS PONT
Combination Hormone Therapy Linked to Increased Risk for Lung Cancer Mortality
Patients may ask about a widely reported study showing a link between hormone therapy (HT) and lung cancer mortality. The findings were reported Saturday at the American Society of Clinical Oncology's annual meeting.
The analysis, performed among some 16,600 Women's Health Initiative participants, found that women taking estrogen-progestin faced increased risk for death from non–small-cell lung cancer, compared with placebo recipients. (Lung cancer incidence did not differ significantly between the groups.)
The New York Times quotes the study's lead author saying that women should not use combination HT and tobacco at the same time.
In response, Journal Watch Women's Health Editor-in-Chief Andrew Kaunitz says: "It's premature to state that menopausal women who smoke should not use HT. Such women have more vasomotor symptoms and higher risks for osteoporotic fractures and coronary artery disease — and HT reduces vasomotor symptoms, prevents osteoporotic fractures, and, in women in their 50s, appears to reduce CAD." He concludes that this area "clearly" deserves more study, but in the meantime, clinical efforts should focus on helping patients to quit smoking.
http://firstwatch.jwatch.org/cgi/content/full/2009/601/2
Further news
